Q-omics provides the consensus-scored SLC2A1-AS1 profile across patient tissues and cancer cell-line models. SLC2A1-AS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SLC2A1-AS1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SLC2A1-AS1 RNA expression shows 16,207 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, KIRC, and UVM as cancer lineages where SLC2A1-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2A1-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2A1-AS1 survival associations across molecular data types. SLC2A1-AS1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2A1-AS1 RNA expression–survival associations across cancer types. High SLC2A1-AS1 expression shows unfavorable associations in LUAD, LIHC, COAD, KICH and KIRP, but favorable associations in CHOL. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUAD as the clearest survival context for SLC2A1-AS1 RNA expression.
This table summarizes SLC2A1-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC2A1-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2A1-AS1 shows higher tumor expression in KIRC, HNSC, LUSC, LUAD, BRCA and LIHC. The KIRC box plot shows higher SLC2A1-AS1 RNA expression in tumor versus normal tissue (log2 FC = +0.466, t-test p < 0.001).
This table shows molecular features associated with SLC2A1-AS1 in patient tissues and cancer cell lines. In patient samples, SLC2A1-AS1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
